| Autor: |
Khwaja, Jahanzaib, Bomsztyk, Joshua, Atta, Maria, Bygrave, Ceri, Forbes, Adam, Durairaj, Senthil, Fernandes, Savio, Taylor, James, Paterson, Pamela, Brearton, Gillian, Crawley, Charles, Sheehy, Oonagh, Brown, Rachel, Soutar, Richard, Garg, Mamta, Rydzewski, Andrzej, Jamroziak, Krzysztof, Mahmood, Shameem, Wechalekar, Ashutosh D. |
| Předmět: |
|
| Zdroj: |
British Journal of Haematology; May2024, Vol. 204 Issue 5, p1811-1815, 5p |
| Abstrakt: |
Summary: Systemic light chain (AL) amyloidosis is a relapsing plasma cell disorder. Therapy is limited, particularly for triple‐class refractory disease. We report the use of belantamab mafodotin, a BCMA‐directed drug–antibody conjugate, for relapsed AL amyloidosis, including patients traditionally excluded from clinical trials. Thirty‐one patients were reviewed, with a median of three prior lines of therapy. The median follow‐up was 12 months (95% CI 4–19), and a median of five doses were delivered. The best haematological overall response rate was 71%, and the complete/very good partial response was 58%. Sixty‐eight percent had keratopathy and improved in all. Belantamab mafodotin has high efficacy and good tolerability in patients with relapsed AL amyloidosis. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text